Gefitinib (IRESSA) as a second-line treatment for advanced non-small cell lung cancer patients who failed first-line chemotherapy in Korea.

Park, BB; Park, JO; Kim, SW; Kim, JH; Shin, SW; Ahn, MJ; Choi, JH; Lee, JS; Park, K

Detailed Information

Cited 0 time in webofscience

Cited 0 time in scopus

Metadata Downloads

Gefitinib (IRESSA) as a second-line treatment for advanced non-small cell lung cancer patients who failed first-line chemotherapy in Korea.

Authors: Park, BB; Park, JO; Kim, SW; Kim, JH; Shin, SW; Ahn, MJ; Choi, JH; Lee, JS; Park, K

Issue Date: 20051215

URI: https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/43869

Conference Name: CLINICAL CANCER RESEARCH

Place: 미국
Philadelphia, PA

Conference Name: AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics

ISSN: 1078-0432
1557-3265

Files in This Item: There are no files associated with this item.

Appears in Collections: 2. Clinical Science > Department of Medical Oncology and Hematology > 2. Conference Papers

Show full item record

qrcode

Related Researcher

Researcher Shin, Sang Won photo

Shin, Sang Won: Anam Hospital (Department of Medical Oncology and Hematology, Anam Hospital)

Read more

Altmetrics

Total Views & Downloads

STATISTICS: Total View :12,733,385; Today View :17,173

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Related Researcher

Altmetrics

Total Views & Downloads

BROWSE